文献速递免疫规划卫生政策与健康促进

探索疫苗超说明书使用:全球国家免疫技术咨询小组网络调查

Exploring off-label vaccine use: a survey of the global national immunization technical advisory group network.
PubMed 文献 · Vaccine · 2025-08-12

该调查向世界卫生组织成员国国家免疫技术咨询小组代表发放在线问卷,评估新冠疫情以来中低收入和高收入国家超说明书疫苗推荐的采纳与趋势。76个国家参与,68%报告其国家免疫技术咨询小组做出超说明书推荐,但仅15%有支持实施的政策和程序。疫情期间及之后超说明书推荐比例上升,各国授权和运行能力存在差异。

要点

  • 76个国家参与调查,68%报告国家免疫技术咨询小组做出超说明书疫苗推荐。
  • 2022年前48%国家推荐超说明书疫苗,2022年后升至58%,不确定比例降至0%。
  • 仅15%国家有支持超说明书推荐实施的政策和程序。

核心结论

  • 尽管世界卫生组织广泛提供国家免疫技术咨询小组授权和核心职能的指导,但全球各国在超说明书疫苗使用方面的授权和运行能力存在差异。
  • 这些发现提示需要提高对超说明书疫苗推荐的认识,并加强围绕超说明书推荐实施的对话。

研究设计与样本

  • 在线问卷调查,发放给世界卫生组织成员国的国家免疫技术咨询小组代表,邀请所有六个世界卫生组织区域的受访者参与。
  • 调查问题涉及参与者所在国家国家免疫技术咨询小组的超说明书疫苗使用政策、程序、立法和法规。

主要发现

  • 76个国家受访者参与调查,其中55%为国家免疫技术咨询小组代表,45%为免疫规划管理者或国家免疫技术咨询小组秘书处人员。
  • 52名(68%)受访者报告其国家免疫技术咨询小组做出超说明书推荐,18名(24%)表示不做超说明书推荐,6名(8%)不确定其国家免疫技术咨询小组的角色。
  • 2022年前,25名(48%)受访者表示其国家推荐超说明书疫苗,11名(21%)表示超说明书推荐仅限于紧急情况下的临时或条件性扩展,6名(12%)不确定。
  • 2022年后,30名(58%)受访者表示其国家推荐超说明书疫苗,4名(8%)表示超说明书推荐仅限于紧急情况下的临时或条件性扩展,18名(35%)选择否,0名(0%)不确定。
  • 大多数国家做出超说明书推荐,但少数(15%)有支持实施的政策和程序。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National Immunization Technical Advisory Groups (NITAGs) are crucial for enhancing vaccine use in immunization programs, particularly through off-label recommendations. This study sought to assess the adoption and trends of off-label vaccine recommendations made by NITAGs across low-, middle-, and high-income countries since the COVID-19 pandemic. METHODS: An online survey was distributed to NITAG representatives in World Health Organization (WHO) member states, asking questions related to off-label use of vaccines including policies, procedures, legislation, and regulations for NITAGs in participants' countries. Respondents across all six WHO regions were invited to participate. RESULTS: Respondents from 76 countries participated in the survey (55 %) were NITAG representatives, and 45 % were immunization program managers or from the NITAG secretariat). Most respondents 52 (68 %) reported their NITAG makes off-label recommendations, 18 (24 %) indicated their NITAG does not make off-label recommendations, and 6 (8 %) were unsure of their NITAG's role. There was a noticeable shift relating to off-label vaccine recommendations observed pre, during, and post-pandemic period. Prior to 2022, 25 (48 %) respondents indicated their country recommended off-label vaccines, 11 (21 %) specified off-label recommendations were limited to emergencies as temporary or conditional expansions, and 6 (12 %) were unsure. After 2022, 30 (58 %) respondents indicated their country recommended off-label vaccines, 4 (8 %) specified off-label recommendations were limited to emergencies as temporary or conditional expansions, 18 (35 %) selected no, and 0 (0%) were unsure. While most countries make off-label recommendations, few (15 %) have policies and procedures to support implementation. CONCLUSIONS: Although WHO broadly provides guidance on the mandate and core functions of NITAGs, globally, they have differing mandates and operational capacities related to off-label vaccine use. These findings suggest the need for increased awareness of off-label vaccine recommendations and strengthened dialogue around implementation of off-label recommendations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Roberts C, Top KA, Henaff L, et al. Exploring off-label vaccine use: a survey of the global national immunization technical advisory group network. Vaccine. 2025. PMID: 40803145. doi:10.1016/j.vaccine.2025.127581

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。